

**Meeting Room 3&4**  
**Hilton Sydney Hotel**  
**488 George St**  
**Sydney NSW 2000**

12.30 – 1.00 pm	Registration	
1.00 – 1.05 pm	Welcome and introductions	N Pavlakis
1.05 – 2.30 pm	<p><b>Updates on trials and concepts in development</b></p> <ul style="list-style-type: none"> <li>i. ALTG 14/001 BR.31 (McLachlan)</li> <li>ii. ALTG 14/002 NIVORAD (Mitchell)</li> <li>iii. ALTG 15/003 DREAM (Nowak)</li> <li>iv. ALTG 13/008 PEARL (Mileshkin)</li> <li>v. ALTG 15/004 BR.34 (TBD)</li> <li>vi. ALTG 16/002 fear of recurrence (McLachlan)</li> <li>vii. ALTG 16/003 optimal duration of immunotherapy (O'Byrne)</li> <li>viii. ALTG 16/004 immunotherapy in SCLC with brain metastases (Mitchell)</li> <li>ix. ALTG 16/005 OSCILLATE alternating osimertinib/gefitinib in EGFR T790M NSCLC (Solomon)</li> <li>x. ALTG 16/007 Alternating crizotinib/lorlatinib in ALK+ NSCLC (Pavlakis)</li> <li>xi. ALTG 16/008 Avelumab + nintedanib in NSCLC (Pavlakis)</li> <li>xii. ALTG 16/009 (b) Durvalumab + tremelimumab in relapsed EGFR mutant NSCLC (Lee)</li> <li>xiii. ALTG 16/010 Primary care vs hospital-based follow-up after surgical lobectomy for NSCLC (Brims)</li> </ul>	<p>S McLachlan  P Mitchell  P S Kok  A Livingstone  M Stockler  P S Kok  K O'Byrne  P Mitchell    B Solomon    P Mitchell    N Pavlakis    N Pavlakis  M Stockler    TBC</p>
2.30 – 3.00 pm	Break	
3.00 – 3.30 pm	<p><b>New concepts for group consideration</b></p> <p><b>For endorsement:</b> Activities and influence of the specialist lung cancer nurse: A mixed-method comparative study of the multidisciplinary team assigned and not assigned a specialist lung cancer nurse (Brunelli/ANZ LCNF)</p> <p><b>For participation:</b> ETOP/IFCT 4-12 STIMULI</p>	<p>V Brunelli    P Mitchell</p>
3.30 – 4.30 pm	Portfolio gap analysis and prioritisation	All
4.30 – 4.45 pm	Summary, next steps	N Pavlakis

Note: ALTG 16/006 ramucirumab + osimertinib in 2L EGFR T790M NSCLC (Mitchell) is not progressing